[Image]

Debashis Sahoo, PhD

Assistant Professor
Department of Pediatrics
Department of Computer Science and Engineering
University of California San Diego
[Logo]
9500 Gilman Drive, MC 0703
Biomedical Research Facility II, Room 2119
La Jolla, CA 92093-0703
Phone: 858-246-1803
Fax: 858-246-0019
Laboratory Address:
9500 Gilman Drive, MC 0703
Leichtag Building 132
La Jolla, CA 92093-0703
Phone: 858-246-1803
Fax: 858-246-0019
Emails:

Postdoc:
Instructor of Pathology and Siebel Fellow at
Institute of Stem Cell Biology and Regenerative Medicine
Stanford University, Stanford, CA 94305-5461

Education:
Ph.D. 2008, M.S. 2003 BTech 2000
Department of Electrical Engineering
Stanford University
Stanford, CA 94305 (USA)
Department of Computer Science and Engineering
Indian Institute of Technology
Kharagpur-721302, (India)

Ph.D. Thesis: Boolean analysis of high-throughput biological datasets
Ph.D. University/Date: Stanford University, September 25, 2008
Ph.D. Advisor: David L. Dill, Co-advisor: Sylvia K. Plevritis

List of publications

Research:
My research is on developing new methods to analyze high-throughput biological datasets. We have developed several tools and techniques to analyze large collections of microarray datasets. Some of my tools that analyze gene expression datasets are StepMiner, BooleanNet and MiDReG .
Teaching (Stanford):
  • StemRem 201 - Fall 2013
  • StemRem 201 - Fall 2012
  • Teaching (UCSD):
  • CSE100: Advanced Data Structures (Spring 2015)
  • CSE100: Advanced Data Structures (Fall 2015)
  • CSE100: Advanced Data Structures (Fall 2016)
  • CSE100: Advanced Data Structures (Fall 2017)
  • CSE291 H00: Impact of formal methods - Bio (Winter 2018)

  • News:
  • [NEJM] CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
  • [UCSD] New Biomarker Identifies Colon Cancer Patients Who May Benefit from Chemotherapy. Colon cancer patients lacking the protein CDX2 have a poorer prognosis than patients with CDX2 but in some cases are more likely to benefit from chemotherapy.
  • [CUMC] Biomarker Predicts Which Stage II Colon Cancer Patients May Benefit from Chemotherapy. Biomarker is detectable with simple, inexpensive test.
  • [Stanford] Chemotherapy may benefit subgroup of stage-2 colon cancer patients. A small subset of colon cancers lacks the CDX2 protein -- a hallmark of colon tissue maturation. Patients with these cancers may benefit more than others from chemotherapy.

  • My Favorite Links Highlights